ABEONA THERAPEUTICS INC.

Abeona Therapeutics Inc. announced that Michael Amoroso resigned from its Board of Directors, effective June 11, 2026. He also stepped down from the Nominating and Corporate Governance Committee. The company stated that his resignation was for personal reasons and not due to any disagreements regarding the company's operations, policies, or practices.

Abeona Therapeutics Inc. has filed an updated investor presentation with the SEC. This presentation, dated June 10, 2026, is intended for use in discussions with investors, analysts, and other stakeholders. The information was furnished under Regulation FD Disclosure.

Abeona Therapeutics Inc. held a constructive Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA) on June 3, 2026. The discussion focused on ABO-701, a recently licensed engineered T-cell therapy targeting Prostate-Specific Membrane Antigen to treat prostate cancer. The company maintains its target of submitting an IND application for ABO-701 in 2027, aligning with its previously announced timeline, though it acknowledges the FDA may request further studies or data.

Abeona Therapeutics Inc. announced it has granted equity awards to seven new non-executive employees as a material inducement to employment. The awards, approved by the Compensation Committee on May 31, 2026, total up to 13,800 restricted shares of common stock. These shares will vest yearly over three years, subject to continued employment. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).

Abeona Therapeutics Inc. announced that its management team will participate in two upcoming investor conferences in June 2026. The company will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, including a fireside chat and investor meetings. Additionally, management will hold investor meetings at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. A live webcast of the Jefferies fireside chat will be available on the company's investor relations website.

Abeona Therapeutics reported its first product revenue of $8.72 million for the first quarter of 2026, driven by the commercialization of ZEVASKYN® following its FDA approval in April 2025. Despite this, the company's net loss widened to $(17.08) million, or $(0.30) per share, compared to a net loss of $(12.03) million in the prior year's quarter, primarily due to increased operating expenses. Abeona also highlighted the recent licensing of ABO-701 for prostate cancer and stated that its capital resources are expected to fund operations for at least the next 12 months.

Abeona Therapeutics reported Q1 2026 net product revenue of $8.7 million, a significant increase from $2.4 million in Q4 2025, driven by ZEVASKYN adoption with three patients treated. The company's net loss widened to $(17.1) million, or $(0.30) per share, compared to $(12.0) million in Q1 2025. Abeona also in-licensed ABO-701, a novel engineered T-cell therapy for prostate cancer, and plans to file an IND in H2 2027, while deprioritizing its ophthalmology programs. Cash, cash equivalents, and short-term investments stood at $168.3 million.

Abeona Therapeutics Inc. announced its Annual Meeting of Stockholders will be held virtually on June 12, 2026. Stockholders will vote on five proposals, including the election of three Class 1 directors, an advisory vote on executive compensation, and the ratification of Deloitte & Touche LLP as the independent auditor. Key proposals also include increasing the shares reserved for the 2023 Equity Incentive Plan from 8.4 million to 11.5 million and removing the advance notice provision for director nominations from the Company's Certificate of Incorporation.

Abeona Therapeutics Inc. announced its Annual Meeting of Stockholders will be held virtually on June 12, 2026. Stockholders will vote on the election of three Class 1 directors, an advisory resolution on executive compensation, and the ratification of Deloitte & Touche LLP as the independent auditor. Key proposals also include increasing shares reserved for the 2023 Equity Incentive Plan from 8.4 million to 11.5 million and amending the Certificate of Incorporation to remove the advance notice provision for director nominations.

Abeona Therapeutics Inc. announced the appointment of Keith A. Goldan to its Board of Directors as a Class 1 director, effective April 1, 2026. This appointment expands the Board from nine to ten members. Mr. Goldan will also serve as Chair of the Audit Committee, bringing independent oversight to the company's financial reporting. His compensation package includes an annual cash fee of $50,000 and a one-time sign-on equity grant valued at $150,000 in restricted stock, vesting over one year, aligning his interests with long-term shareholder value.